Blog Archives

ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES USE OF MULTI-CRITERIA DECISION ANALYSIS TO SUPPORT HEALTH TECHNOLOGY ASSESSMENT

Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held a workshop this morning entitled, The Potential and Pitfalls of Using Multi-Criteria Decision Analysis to Support Health Technology Assessment. The session took place at the Society’s 19th

Tagged with: , , , ,
Posted in Announcements, ISPOR News & Press

ISPOR 21st ANNUAL INTERNATIONAL MEETING CONVENED KEY HEALTH CARE STAKEHOLDERS IN WASHINGTON, DC

Nancy Berg, ISPOR CEO

Princeton, NJ—June 9, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting recently concluded in Washington, DC, USA. Government officials, health ministries, and global thought leaders in health economics and outcomes research (HEOR) from more than

Tagged with: , , , , , , , , , , , , , ,
Posted in Announcements, ISPOR News & Press

ISPOR 21ST ANNUAL INTERNATIONAL MEETING ISSUE PANEL CONSIDERS MCDA AS A POSSIBLE NEW PARADIGM IN HEALTH CARE DECISION MAKING

Washington, DC—May 24, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting Issue Panel 12—Multi-Criteria Decision Analysis: A New Paradigm in Health Care Decision Making? What Are the Current Status, Challenges, and Opportunities?—was held this afternoon

Tagged with: , , , , , , ,
Posted in Announcements, ISPOR News & Press

ISPOR PUBLISHES TASK FORCE REPORT #2 ON MULTIPLE CRITERIA DECISION ANALYSIS

VIH-Cover_19-2

Second Report Published in March/April Issue of Value in Health Princeton, NJ—April 5, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) published a new Task Force Report, “Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report

Tagged with: , , , , , , , , , , , ,
Posted in Announcements, Brief Report, ISPOR News & Press, Value in Health

ISPOR PUBLISHES NEW TASK FORCE REPORT ON MULTIPLE CRITERIA DECISION ANALYSIS

Value in Health - January-February 2016

First of Two Reports Published in Value in Health Princeton, NJ—January 26, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) published a new Task Force Report, “Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of

Tagged with: , , ,
Posted in Announcements, ISPOR Journals, ISPOR News & Press, Value in Health

ISPOR’s 3rd PLENARY OF 18th ANNUAL EUROPEAN CONGRESS DISCUSSES MULTI-CRITERIA DECISION ANALYSIS (MCDA)

PANEL REVIEWS RECOMMENDATIONS FROM ISPOR’s MCDA EMERGING GOOD PRACTICE TASK FORCE  Milan, Italy—November 11, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress third plenary session — Recommendations from the ISPOR Multi-Criteria Decision Analysis Emerging Good

Tagged with: , ,
Posted in Announcements, ISPOR News & Press

ISPOR EUROPEAN CONGRESS FOCUSES ON “IMPACTING HEALTH DECISION MAKING WITH OUTCOMES RESEARCH”

18th ANNUAL CONGRESS TO BE HELD 7-11 NOVEMBER, 2015 IN MILAN, ITALY  Princeton, NJ—November 2, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced confirmation of key scientific sessions for its 18th Annual European Congress starting next week, 7-11

Tagged with: , , , , , , , , , , ,
Posted in Announcements, ISPOR News & Press

ISPOR 18th ANNUAL EUROPEAN CONGRESS REGISTRATION AT RECORD HIGH

ISPOR-20th-Anniversary-logo

Princeton, NJ—October 13, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today that its 18th Annual European Congress has registered a record number of delegates for this annual meeting. The Congress will be held 7-11 November 2015 in

Tagged with: , , , ,
Posted in Announcements, ISPOR News & Press

Valuing Rare Disease Medicines – We Can Do Better

London, United Kingdom – Many rare diseases, often severe and life-threatening, cannot be treated. The small numbers of patients affected make it time-consuming and costly to compile evidence about treatments. Organisations that pay for health care recognise that a special approach

Tagged with: , , , ,
Posted in Brief Report, Value in Health
Categories
Follow ISPOR
RSS FeedFriend me on FacebookFollow my company on LinkedInFollow me on TwitterWatch me on YouTube